ACR	American College of Rheumatology
anti-TNF	Anti-tumor necrosis factor
APR	Acute-phase reactants
AS	Ankylosing spondylitis
ASAS40	Assessment of SpondyloArthritis International Society 40% response
ASDAS	Axial Spondyloarthritis Disease Activity Score
AtheSpAin	Atherosclerosis in Spondyloarthritis cohort
axSpA	Axial spondyloarthritis
BASDAI	Bath Ankylosing Spondylitis Disease Activity Index
bDMARDs	Biologic disease-modifying antirheumatic drugs
BMI	Body mass index
BP	Blood pressure
b/tsDMARDs	Biologic and targeted synthetic disease-modifying antirheumatic drugs
CHD	Coronary heart disease
CRP	C-reactive protein
csDMARDs	Conventional synthetic disease-modifying antirheumatic drugs
CV	Cardiovascular
CVD	Cardiovascular disease
DAPSA	Disease Activity Index for Psoriatic Arthritis
DIP	Distal interphalangeal
ESR	Erythrocyte sedimentation rate
HDL-C	High-density lipoprotein cholesterol
HLA-B27	Human leukocyte antigen B27
HR	Hazard ratio
IBD	Inflammatory bowel disease
IBP	Inflammatory back pain
IFNα	Interferon alpha
IL	Interleukin
IL-12/23i	Interleukin-12/23 inhibitor
IL-17i	Interleukin-17 inhibitor
IL-23i	Interleukin-23 inhibitor
IMT	Intima-media thickness
JAKi	Janus kinase inhibitor
MACE	Major adverse cardiovascular events
MASES	Maastricht Ankylosing Spondylitis Enthesitis Score
MDA	Minimal disease activity
MHC	Major histocompatibility complex
MRI	Magnetic resonance imaging
NSAIDs	Non-steroidal anti-inflammatory drugs
nr-axSpA	Non-radiographic axial spondyloarthritis
OR	Odds ratio
PsA	Psoriatic arthritis
PsO	Psoriasis
r-axSpA	Radiographic axial spondyloarthritis
SCORE	Systematic Coronary Risk Evaluation
SIJ	Sacroiliac joint
SpA	Spondyloarthritis
TIA	Transient ischaemic attack
TNFi	Tumor necrosis factor inhibitor
VTE	Venous thromboembolism